Sanofi CEO Finally Scores With $11.6B Buyout of Biogen's Spinoff Bioverativ Post author:Sam Post published:January 21, 2018 Post category:BioPharma The deal has Sanofi paying $105 per share in cash. Source: BioSpace You Might Also Like University Enterprise Laboratories Announces Partnership With (UMGC) July 13, 2017 Juno Therapeutics Spinout Raises $90M March 7, 2018 Pharming Group Report On Preliminary Financial Results For 2016 March 8, 2017
